Company intelligence / Profile preview
IsletRegen
Duarte, California, United Statesisletregen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
IsletRegen is a biotechnology company focused on developing regenerative medicine therapies for the treatment of Type 1 diabetes. The company leverages a proprietary platform designed to regenerate functional pancreatic islet cells, aiming to restore endogenous insulin production in patients. By focusing on the underlying cellular deficiency of the disease, IsletRegen seeks to provide a long-term alternative to exogenous insulin therapy. Their approach combines advanced cell biology with regenerative techniques to create a sustainable source of insulin-producing cells. The company is currently in the pre-clinical stage, advancing its lead programs toward regulatory filings.
- Therapeutic areas
- Endocrinology
- Modalities
- Cell therapyBiologicRegenerative medicine
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on IsletRegen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IsletRegen.